Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between ...

YolTech's gene therapy is intended as a one-time life-long cure for patients living with PH1, which can lead to kidney ...

Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

ElevateBio is seeking out partnerships for its lead gene therapy after the construct reduced the levels of a toxic protein in ...

A study led by UMass Chan researchers demonstrated that a gene therapy to correct a mutation that causes maple syrup urine ...

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...

Artificial intelligence is making waves across industries, but its impact is higher in some sectors than others. Medicine and other sciences stand to gain much from this technology, thanks to their ...

Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD ...

Recombinase efficiency increases allow Qi Biodesign to insert 20-30 kb (5 or 6 genes) at one time at one location across a variety of different crop genetics. In addition, a large team at Qi Biodesign ...

PH1, the most common subtype, is triggered by AGXT gene mutations and typically manifests in childhood. Patients often present with kidney stones, nephrocalcinosis, renal insufficiency, and oxalate ...